LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Nanomaterial-Based Diagnostic Technology Accurately Monitors Drug Therapy in Epilepsy Patients

By LabMedica International staff writers
Posted on 13 Nov 2024
Image: Schematic diagram of nanomaterial-based anti-epileptic drug concentration diagnostic technology (Photo courtesy of KRISS)
Image: Schematic diagram of nanomaterial-based anti-epileptic drug concentration diagnostic technology (Photo courtesy of KRISS)

Many patients with epilepsy take anti-epileptic drugs to control frequent seizures in their daily lives. To optimize treatment and avoid side effects from overdosing, it is crucial for patients to regularly monitor the concentration of these drugs in their bodies. However, the current diagnostic technologies used in hospitals for this purpose face challenges in terms of both accuracy and time efficiency. The most widely used method, immunoassay, is prone to cross-reactions with similar drugs, which lowers diagnostic accuracy. While mass spectrometry, which ionizes samples using electrospray, offers greater accuracy, it is time-consuming and expensive, creating additional burdens for patients. To address these limitations, researchers have developed a novel diagnostic and treatment system based on nanomaterials for therapeutic drug monitoring (TDM) in epilepsy patients. This approach promises to significantly reduce the time and cost of current diagnostics while maintaining accuracy, ultimately easing the burden on patients managing their condition.

This innovative nanomaterial-based diagnostic method was developed by scientists at the Korea Research Institute of Standards and Science (KRISS, Daejeon, South Korea), in collaboration with domestic university hospitals. By incorporating a mixture of molybdenum ditelluride (MoTe2) and tungsten ditelluride (WTe2) nanosheets into the sample and ionizing it with a laser, the researchers were able to enhance both the speed and sensitivity of drug detection. When applied to samples from 120 epilepsy patients, the technology demonstrated over 99.9% reliability, while reducing the analysis time to just one-sixteenth of the original. Furthermore, the number of samples that could be analyzed in a single session increased more than tenfold, potentially cutting diagnostic costs by half.

Related Links:
KRISS

Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Sample Transportation System
Tempus1800 Necto
Laboratory Software
ArtelWare

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more